Modafinil racemate received as a micronized powder with a D90 specification not exceeding 45 µm is dry-blended with lactose monohydrate, microcrystalline cellulose PH102, and croscarmellose sodium in a 600 L diffusion blender at 12 rpm for 240 s. Before the final lubrication step, the powder is passed through a 600 µm aperture sieve to break soft agglomerates; API lots that retain more than 1.5 wt% moisture at 105°C are pre-dried in a fluid-bed dryer with inlet air at 40°C until loss on drying is below 1.0%. Magnesium stearate at 0.5 wt% is introduced as the last excipient and mixed for 5 min at 10 rpm. The lubrication window is deliberately narrow because hydrophobic film formation on the micronized sulfoxide surface retards wetting and produces dissolution lag times exceeding 10 min in 0.1 N HCl containing 0.5% sodium lauryl sulfate, as measured by USP 〈711〉 Apparatus 2 at 50 rpm.

Compression of the 200 mg strength is executed on a rotary tablet press fitted with 10 mm standard concave round punches; precompression force is fixed at 1.5 kN to evacuate air, while main compression force is adjusted between 8 kN and 12 kN to produce tablets with hardness 6–9 kp. Friability is kept below 0.5% per Ph. Eur. 2.9.7, and disintegration is required to complete within 15 min in water at 37°C per Ph. Eur. 2.9.1. Overcompression above 12 kN increases internal elastic recovery of the API and causes capping at the tablet crown; undercompression below 8 kN raises friability and may prolong disintegration because pore channels collapse under the coating pan load.

Film coating is applied as a 3 wt% weight gain of polyvinyl alcohol-based aqueous dispersion in a perforated side-vented pan. Inlet air temperature is maintained at 60–70°C, bed temperature 38–42°C, atomization pressure 1.2 bar, and pan speed 8 rpm. Humidity in the coat zone above 60% RH causes logo bridging and inter-tablet sticking; the spray rate is reduced when exhaust relative humidity exceeds 55%. Coated tablets are reconciled as a controlled substance per 21 CFR 1304.21 because modafinil is listed in Schedule IV under 21 CFR 1308.14(e).

What limits content uniformity in Modafinil capsule filling?

Hard gelatin or hydroxypropylmethylcellulose capsule filling of Modafinil is a powder segregation problem rather than a dissolution problem. The micronized API has a low tapped bulk density near 0.30 g/cm³ and adheres to metal transfer surfaces; therefore it is first de-lumped through a 500 µm cone mill at 2000 rpm and preblended with a 1:1 mixture of lactose monohydrate and pregelatinized starch in a 300 L bin blender at 10 rpm for 300 s. Talc at 1.0 wt% is included as a glidant. Final capsule fill weight for a 200 mg dose is 310 mg in size 1; for a 100 mg dose the fill weight is reduced to 155 mg in size 3. Content uniformity is assessed by Ph. Eur. 2.9.40 with an acceptance value not more than 15.0.

On a tamping-pin capsule machine, the powder bed depth is controlled at 25–35 mm, and the tamping pin penetration depth is set at 3.0–4.0 mm from zero to compress the slug without crushing the API crystals. Relative humidity is held below 40% during filling because the powder becomes cohesive above 45% RH and sticks to the dosator nozzle. In-process weight checks are performed with an automatic checkweigher at 120–180 capsules/min; batches with weight variation above 3.0% RSD are rejected because low-dose content uniformity correlates with fill weight variability.

Wet granulation of Modafinil for oral granules is performed in a top-driven high-shear mixer-granulator fitted with a 4 L bowl, main impeller speed 300 rpm, and chopper speed 1500 rpm. Purified water is delivered through a 0.8 mm two-fluid nozzle at 20 g/min until a torque value of 45–55 N·cm is reached; water addition is then stopped and the wet mass is kneaded for 60 s. Overgranulation beyond 55 N·cm produces dense agglomerates that pass the 850 µm screen but disintegrate slowly because the intragranular pores become filled with binder; the batch is discarded if the power consumption curve shows a second torque rise after the water pump stops.

The granulate is dried in a fluid-bed dryer at 60°C inlet air until loss on drying is 1.5–2.0%, then sized through a 1000 µm sieve and blended with extragranular croscarmellose sodium at 2 wt% and xylitol at 5 wt% before sachet filling on a strip-pack machine at 40–60 sachets/min. Seal integrity is tested by methylene blue leak test per Ph. Eur. 2.9.5; any sachet showing blue penetration is rejected. The granular presentation is intended for sprinkling on soft food or for dispersion in 30 mL water, and its dissolution is evaluated by USP 〈711〉 Apparatus 2 in 0.1 N HCl with 0.5% sodium lauryl sulfate.

Injectable Modafinil is constrained by cosolvent fraction, not by micronization

Modafinil injection is not represented by a compendial monograph; developmental batches are compounded in a barrier isolator and designed around a solubility limit near 0.1 mg/mL in water. The un-ionized amide-sulfoxide molecule does not respond to pH adjustment across the physiological range, so solubility enhancement is attempted with hydroxypropyl-β-cyclodextrin or with PEG 300/propylene glycol mixtures. Published data for this specific configuration is limited; phase-solubility screening per Higuchi–Connors at 25°C is required before committing to a sterile batch. When a cosolvent system is used, the API is first dissolved in PEG 300 at 20–30 vol% of final formulation volume, then diluted with Water for Injection; reversing the solvent order precipitates the poorly soluble free form and clogs the mixing vessel filter housing.

Terminal sterilization of an aqueous Modafinil solution at 121°C for 15 min is generally avoided because forced-degradation studies per ICH Q1A(R2) show amide hydrolysis under acidic and alkaline stress and sulfoxide oxidation to the sulfone in dilute peroxide. The sterile batch is therefore sterile-filtered through a 0.22 µm PVDF membrane with pre-rinsing until total organic carbon is below 0.5 mg/L and filled under nitrogen headspace. Subvisible particulate matter is controlled per USP 〈788〉; for containers of 100 mL or less, the light-obscuration limits are not more than 6000 particles ≥10 µm and not more than 600 particles ≥25 µm per container. Osmolality is adjusted to 280–320 mOsm/kg with mannitol rather than sodium chloride when high cosolvent fractions reduce electrolyte solubility.

When Modafinil is lyophilized with mannitol for injectable reconstitution, the collapse temperature dictates the primary drying shelf setpoint

Lyophilized Modafinil is developed by freezing a 10 mg/mL solution containing 4% mannitol and 0.5% glycine in 10 mL type I tubing glass vials. Differential scanning calorimetry at 10°C/min and freeze-dry microscopy identify the collapse temperature of the maximally freeze-concentrated amorphous phase; primary drying is set 2–5°C below that value, commonly at shelf −35°C with chamber pressure 80 mTorr for 36 h. The exact temperature must be re-measured for each cosolvent-loaded formulation because PEG 300 and propylene glycol lower the glass transition and narrow the primary-drying window. If the product temperature exceeds collapse temperature, the cake shrinks and reconstitution time increases beyond 120 s.

Secondary drying is ramped to 40°C at 0.5°C/min and held for 6 h until residual moisture is below 0.8% by coulometric Karl Fischer per USP 〈921〉. Vial heat transfer coefficients are influenced by lot-to-lot bottom glass thickness; a 0.2 mm variation in glass thickness can shift product temperature by 1–2°C. The lyophilized cake is reconstituted with 5 mL Water for Injection; clarity is acceptable only when cyclodextrin is present in the formulation, otherwise the suspension is unsuitable for intravenous administration without further filtration.

Compounded oral suspension prepared from tablets and pure API in a USP 795 setting

Pediatric or geriatric patients who cannot swallow the tablet are served by a compounded oral suspension prepared under USP 〈795〉. The pure API is levigated with 0.5% polysorbate 80 and a small volume of glycerol to wet the hydrophobic crystals, then incorporated into a 1:1 vehicle of Ora-Plus and Ora-Sweet or a sugar-free suspending base. The compounding concentration is typically 10 mg/mL; the suspension is packaged in amber polyethylene terephthalate bottles and stored at 2–8°C. Without stability-indicating data, the beyond-use date is limited to 14 days per USP 〈795〉. Physical stability is monitored by sediment volume ratio; if the ratio falls below 0.90 after 24 h, the suspending agent level is adjusted upward in increments of 0.1% carbomer or microcrystalline cellulose/carboxymethylcellulose sodium until resuspension is achieved with 20 s of shaking.

Controlled-substance reconciliation in the compounding pharmacy follows 21 CFR 1304.21, and the prescription must be verified against state-specific Schedule IV records. The finished suspension is labeled with the beyond-use date, storage temperature, and a shake-well instruction. Because modafinil crystals are hydrophobic, adding water directly to the pure powder without a wetting agent produces floating aggregates that cannot be uniformly dispersed; this failure mode is avoided by mixing the API with the surfactant and glycerol before any aqueous vehicle is introduced.